Principia: Test-Time Hypotheses to Principle Construction for Scientific Discovery
Organizations: KAIST
Abstract
Scientific discovery requires identifying the scientific principles underlying observed phenomena to guide further investigation. As these empirical principles are often unknown in complex discovery processes, they are constructed via a hypotheses-to-principle pipeline to obtain recurring causalities from progressively accumulated observations during test-time discovery. However, constructing this knowledge requires substantial domain expertise, time, and effort, making this translation stage a bottleneck for scientific discovery. To address this limitation, we propose Principia, an LLM-based framework that constructs and continually refines scientific principles at test time. Drawing on how human researchers develop principles, Principia forms comparative causal hypotheses from related inputs and their observed outcomes, then synthesizes recurring relationships across these hypotheses into inductive principles. By applying the constructed hypotheses and inductive principles to the task, it obtains new observations, revises the hypotheses used based on these new observations, and reconstructs principles from the updated hypotheses, allowing scientific knowledge to continuously evolve throughout test-time discovery. Across benchmarks spanning molecular optimization, protein engineering, gene perturbation, and molecular property prediction, Principia outperforms baselines relying on internal knowledge, external sources, or experience summaries, while generating principles that are plausible and consistent with the scientific literature, demonstrating its effectiveness in constructing and refining task-specific hypotheses and principles at test time for scientific discovery. Our code is available at https://github.com/DongkiKim95/Principia.
Figures & tables
| JNK3 | GSK3 | Median1 | Median2 | Valsartan Smarts | Avg. | |||||||
| Methods | Avg@100 | AUC@10 | Avg@100 | AUC@10 | Avg@100 | AUC@10 | Avg@100 | AUC@10 | Avg@100 | AUC@10 | Avg@100 | AUC@10 |
| REINVENT | 0.164 | 0.160 | 0.438 | 0.368 | 0.202 | 0.187 | 0.164 | 0.167 | 0.000 | 0.000 | 0.194 | 0.176 |
| Memory-Aug | 0.282 | 0.211 | 0.535 | 0.414 | 0.213 | 0.189 | 0.178 | 0.167 | 0.000 | 0.000 | 0.242 | 0.196 |
| Graph GA | 0.316 | 0.290 | 0.352 | 0.315 | 0.175 | 0.177 | 0.162 | 0.167 | 0.000 | 0.000 | 0.201 | 0.190 |
| [0.5pt/1pt] MolLEO ∗ | 0.266 | 0.273 | 0.400 | 0.341 | 0.293 | 0.280 | 0.197 | 0.189 | 0.018 | 0.028 | 0.235 | 0.222 |
| ExLLM ∗ | 0.245 | 0.227 | 0.438 | 0.363 | 0.293 | 0.281 | 0.198 | 0.190 | 0.096 | 0.188 | 0.254 | 0.250 |
| Protein Sequence Engineering | Gene Perturbation | ||||||||||
| Syn-3bfo | AAV | GB1 | Scharenberg22 | IFNG | Avg. | ||||||
| Methods | Avg@50 | AUC@10 | Avg@50 | AUC@10 | Avg@50 | AUC@10 | Hit Ratio | AUC@10 | Hit Ratio | AUC@10 | AUC@10 |
| MolLEO ∗ | -0.374 | 0.737 | 0.664 | 0.524 | 0.201 | 0.245 | 0.270 | 0.606 | 0.107 | 0.717 | 0.566 |
| ExLLM ∗ | -0.286 | 0.738 | 0.660 | 0.522 | 0.236 | 0.277 | 0.277 | 0.605 | 0.109 | 0.735 | 0.575 |
| PiFlow ∗ | -32.149 | 0.079 | 0.049 | 0.072 | 0.111 | 0.188 | 0.289 | 0.557 | 0.111 | 0.682 | 0.316 |
| WebSearch ∗ | -0.367 | 0.738 | 0.659 | 0.527 | 0.197 | 0.233 | 0.226 | 0.533 | 0.110 | 0.702 | 0.547 |
| DILI | hERG | Ames | Skin | CYP1A2 | CYP2C9 | CYP2D6 | CYP3A4 | Avg. | ||||||||||
| Methods | Acc | F1 | Acc | F1 | Acc | F1 | Acc | F1 | Acc | F1 | Acc | F1 | Acc | F1 | Acc | F1 | Acc | F1 |
| Direct | 52.43 | 44.11 | 51.33 | 37.27 | 58.33 | 57.51 | 45.12 | 43.54 | 63.33 | 60.18 | 67.33 | 64.73 | 68.33 | 66.64 | 60.00 | 54.26 | 58.28 | 53.53 |
| [0.5pt/1pt] Few-shot ( ) | 59.72 | 54.68 | 58.67 | 53.16 | 59.33 | 59.02 | 52.03 | 51.30 | 66.33 | 64.98 | 68.00 | 66.95 | 69.33 | 68.93 | 59.00 | 57.21 | 61.55 | 59.53 |
| Few-shot ( ) | 62.15 | 57.95 | 62.00 | 59.76 | 62.33 | 61.03 | 52.85 | 51.49 | 64.67 | 63.06 | 70.33 | 69.75 | 71.33 | 71.31 | 61.00 | 59.63 | 63.33 | 61.75 |
| Few-shot ( ) | 62.85 | 57.82 | 64.67 | 62.83 | 62.00 | 60.53 | 50.81 | 49.62 | 67.67 | 66.00 | 66.67 | 66.18 | 71.67 | 71.53 | 62.00 | 60.42 | 63.54 | 61.87 |
| Few-shot ( ) | 62.15 | 57.74 | 64.00 | 62.60 | 62.33 | 60.94 | 50.81 | 48.40 | 66.33 | 64.65 | 69.67 | 69.42 | 71.67 | 71.65 | 64.67 | 62.97 | 63.95 | 62.30 |
| (A) Comparative evidence | (B) Causal hypotheses | (C) Inductive principle |
| Mutagenic (+) Mutagenic (+) | The shared aryl ether epoxide motif, … is the most plausible mutagenicity driver because it is retained in both compounds. | Positive pattern Epoxide/oxirane-bearing aryl ether motifs recur as a likely mutagenicity driver, especially Ar-O-CH2-CH … Negative pattern More polar aminoalcohol side chains … are often tolerated when they do not contain a strained electrophile. |
| Mutagenic (+) Non-mutagenic ( ) | mutagenicity is driven by its epoxide/oxirane-like ring … has open-chain alcohol/amine side chain , which is far less prone to covalent DNA damage … |
Appendix figures & tables4 assets
Supplementary material from the paper’s appendix.
Appendix
| Reference & Target | Original Hypothesis |
| Non-inhibitor Inhibitor | Compared with the reference’s thiourea linker , the target’s benzamide linker and substituted aromatic scaffold may contribute to CYP2C9 inhibition. |
| New Observation | Revised Hypothesis |
| Predicted: Inhibitor Observed: Non-inhibitor | An amide motif alone does not reliably explain inhibition; its role must be considered in the context of the surrounding aromatic arrangement . |
Large Language Model-Guided Scientific Discovery
Large language model-guided scientific discovery uses AI to propose, test, and refine hypotheses, models, experiments, and designs.
See all 275 papers